Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2025)

Argenx Se (ARGX) posted Liabilities and Shareholders Equity of $8.7 billion for Q4 2025, up 120903.23% on a QoQ basis from $7.2 million in Q2 2025, and up 39.99% year-over-year from $6.2 billion in Q4 2024.

Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2025) Analysis & Trends

Argenx Se's Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $8.7 billion for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 39.99% year-over-year to $8.7 billion in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $8.7 billion (down 20.99% YoY) and the FY2025 annual result came in at $8.7 billion, up 39.99% from the prior year.
  • Liabilities and Shareholders Equity was $8.7 billion for Q4 2025 at Argenx Se, up from $7.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $8.7 billion in Q4 2025 and bottomed at $7.2 million in Q2 2025.
  • A 5-year average of $4.0 billion and a median of $3.2 billion in 2021 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 50.18% — and 2025, when it tumbled 99.85%.
  • Argenx Se's Liabilities and Shareholders Equity stood at $2.9 billion in 2021, then advanced by 9.96% to $3.1 billion in 2022, then jumped by 44.93% to $4.5 billion in 2023, then surged by 36.55% to $6.2 billion in 2024, then soared by 39.99% to $8.7 billion in 2025.
  • Business Quant data shows ARGX's Liabilities and Shareholders Equity at $8.7 billion in Q4 2025, $7.2 million in Q2 2025, and $6.2 billion in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 311.58 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 78.88 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 33.89 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 8.55 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - 811.27 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 2.25 Bn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 5.13 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 8.68 Bn
Jun 30, 2025 7.18 Mn
Dec 31, 2024 6.20 Bn
Jun 30, 2024 4.80 Bn
Dec 31, 2023 4.54 Bn
Jun 30, 2023 3.19 Bn
Dec 31, 2022 3.13 Bn
Jun 30, 2022 3.25 Bn
Dec 31, 2021 2.85 Bn
Jun 30, 2021 3.21 Bn
Dec 31, 2020 2.21 Bn
Jun 30, 2020 2.23 Bn
Dec 31, 2019 1.59 Bn
Jun 30, 2019 1.13 Bn
Dec 31, 2018 660.25 Mn
Jun 30, 2018 429.66 Mn
Dec 31, 2017 436.72 Mn
Jun 30, 2017 203.95 Mn
Dec 31, 2016 114.20 Mn
Dec 31, 2015 50.38 Mn